Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing, low-grade dermal tumor. Cytogenetic and FISH studies have revealed that the chromosomal rearrangements characteristic of DFSP tumors involve both translocations and the formation of a supernumerary ring derived from chromosomes 17 and 22. The t(17;22) (q22;q13.1) translocation generates a gene fusion between COL1A1 and PDGFB, which serves as a diagnostic marker of DFSP. In the present study we performed array-CGH (aCGH) analysis on ten DFSP tumors. The COL1A1 region at 17q was gained in 71% (5/7) of the samples and the PDGFB region at 22q was gained in 43% (3/7) of the individual samples. In addition to the 17q and 22q gains, altogether 17 minimal common regions of gain and one region of loss were detected.

1.
Atiye J, Wolf M, Kaur S, Monni O, Böhling T, et al: Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 42:158–163 (2005).
2.
Craig DW, Huentelman MJ, Hu-Lince D, Zismann VL, Kruer MC, et al: Identification of disease causing loci using an array-based genotyping approach on pooled DNA. BMC Genomics 6:138 (2005).
3.
Domanski HA, Gustafson P: Cytologic features of primary, recurrent, and metastatic dermatofibrosarcoma protuberans. Cancer 96:351–361 (2002).
4.
El-Rifai W, Larramendy ML, Bjorkqvist AM, Hemmer S, Knuutila S: Optimization of comparative genomic hybridization using fluorochrome conjugated to dCTP and dUTP nucleotides. Lab Invest 77:699–700 (1997).
5.
Jong K, Marchiori E, Meijer G, Vaart AV, Ylstra B: Breakpoint identification and smoothing of array comparative genomic hybridization data. Bioinformatics 200:3636–3637 (2004).
6.
Kendziorski C, Irizarry RA, Chen KS, Haag JD, Gould MN: On the utility of pooling biological samples in microarray experiments. Proc Natl Acad Sci USA 102:4252–4257 (2005).
7.
Kiuru-Kuhlefelt S, El-Rifai W, Fanburg-Smith J, Kere J, Miettinen M, Knuutila S: Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans. Cytogenet Cell Genet 92:192–195 (2001).
8.
Larramendy ML, Kaur S, Svarvar C, Böhling T, Knuutila S: Gene copy number profiling of soft tissue leiomyosarcoma by array-CGH. Cancer Genet Cytogenet 169:94–101 (2006)
9.
Linn SC, West RB, Pollack JR, Zhu S, Hernandez-Boussard T, et al: Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 163:2383–2395 (2003).
10.
Mitelman Database of Chromosome Aberrations in Cancer. Mitelman F, Johansson B, Mertens F (eds.). http://cgap.nci.nih.gov/Chromosomes/Mitelman (2006).
11.
Monni O, Barlund M, Mousses S, Kononen J, Sauter G, et al: Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci USA 98:5711–5716 (2001).
12.
Naeem R, Lux ML, Huang SF, Naber SP, Corson JM, Fletcher JA: Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol 147:1553–1558 (1995).
13.
Nishio J, Iwasaki H, Ohjimi Y, Ishiguro M, Isayama T, et al: Supernumerary ring chromosomes in dermatofibrosarcoma protuberans may contain sequences from 8q11.2-qter and 17q21-qter: A combined cytogenetic and comparative genomic hybridization study. Cancer Genet Cytogenet 129:102–106 (2001).
14.
Nishio J, Iwasaki H, Ohjimi Y, Ishiguro M, Isayama T, et al: Overrepresentation of 17q22-qter and 22q13 in dermatofibrosarcoma protuberans but not in dermatofibroma: A comparative genomic hybridization study. Cancer Genet Cytogenet 132:102–108 (2002).
15.
O’Brien KP, Seroussi E, Dal Cin P, Sciot R, Mandahl N, et al: Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 23:187–193 (1998).
16.
Pedeutour F, Coindre JM, Sozzi G, Nicolo G, Leroux A, et al: Supernumerary ring chromosomes containing chromosome 17 sequences. A specific feature of dermatofibrosarcoma protuberans? Cancer Genet Cytogenet 76:1–9 (1994).
17.
Pedeutour F, Simon MP, Minoletti F, Sozzi G, Pierotti MA, et al: Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res 55:2400–2403 (1995).
18.
Pedeutour F, Simon MP, Minoletti F, Barcelo G, Terrier-Lacombe MJ, et al: Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: A new tumor-associated chromosome rearrangement. Cytogenet Cell Genet 72:171–174 (1996).
19.
Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, et al: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23:41–46 (1999).
20.
Sandberg AA, Bridge JA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet 140:1–12 (2003).
21.
Simon MP, Navarro M, Roux D, Pouyssegur J: Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in dermatofibrosarcoma protuberans (DP). Oncogene 20:2965–2975 (2001).
22.
Sirvent N, Maire G, Pedeutour F: Genetics of dermatofibrosarcoma protuberans family of tumors: From ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 37:1–19 (2003).
23.
Sonobe H, Furihata M, Iwata J, Ohtsuki Y, Chikazawa M, et al: Dermatofibrosarcoma protuberans harboring t(9;22)(q32;q12.2). Cancer Genet Cytogenet 110:14–18 (1999).
24.
Tyybäkinoja A, Saarinen-Pihkala U, Elonen E, Knuutila S: Amplified, lost, and fused genes in 11q23–25 amplicon in acute myeloid leukemia, an array-CGH study. Genes Chromosomes Cancer 45:257–264 (2006).
25.
Vauhkonen H, Vauhkonen M, Sajantila A, Sipponen P, Knuutila S: DNA copy number aberrations in intestinal-type gastric cancer revealed by array-based comparative genomic hybridization. Cancer Genet Cytogenet 167:150–154 (2006).
26.
Zhang SD, Gant TW: Effect of pooling samples on the efficiency of comparative studies using microarrays. Bioinformatics 21:4378–4383 (2005).
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.